

RQ Medical Limited

Unaudited Abridged Financial Statements for the year
ended 10 February 2026

TABLE OF CONTENTS	<i>PAGE</i>
COMPANY INFORMATION	2
DIRECTORS' RESPONSIBILITIES STATEMENT	3
ABRIDGED BALANCE SHEET	5
STATEMENT OF CHANGES IN EQUITY	7
NOTES TO THE FINANCIAL STATEMENTS	8

RQ MEDICAL LIMITED

COMPANY INFORMATION

DIRECTORS	Quintain Noonan (Ireland) Ronan Parkinson (Ireland)
COMPANY SECRETARY	Ronan Parkinson (Ireland)
REGISTERED OFFICE	Gormlee, Carraig na BhFear, Cork.
REGISTERED NUMBER OF INCORPORATION	746780

**DIRECTORS' RESPONSIBILITIES STATEMENT
for the year ended 10 February 2026**

The directors made the following statement in respect of the unaudited financial statements:

General responsibilities

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under the law the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council and promulgated by the Institute of Chartered Accountants in Ireland. Under company law, the directors must not approve the financial statements unless they are stratified that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year end otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- Select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and estimate that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards.
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy and enable them to ensure that the financial statements and directors' report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Directors' declaration on unaudited financial statements

In relation to the financial statements comprising the Profit and Loss Account, the Balance Sheet, the Statement of Cash Flows, the Accounting Policies and the related notes:

The directors approve these financial statements and confirm that they are responsible for them, including selecting the appropriate accounting policies, applying them consistently and making, on a reasonable and prudent basis, the judgements underlying them. They have been prepared on the going concern basis on the grounds that the company will continue in business.

The directors confirm that they have made available, all the company's accounting records and provided all the information, books and documents necessary for the compilation of the financial statements.

The directors confirm that to the best of their knowledge and belief, the accounting records reflect all the transactions of the company for the year ended 10 February 2026 .

DIRECTORS' RESPONSIBILITIES STATEMENT
for the year ended 10 February 2026 (continued)

Signed on behalf of the board

Directors Quintain Noonan

Quintain Noonan

Ronan Parkinson

Ronan Parkinson

Date: 10 Feb 2026

RQ MEDICAL LIMITED**ABRIDGED BALANCE SHEET**
at 10 February 2026

		2026	2025
ASSETS EMPLOYED	<i>Note</i>	€	€
FIXED ASSETS			
Tangible assets		-	-
		<hr/>	<hr/>
CURRENT ASSETS			
Debtors	6	-	-
Cash at bank and in hand		1,000	1,000
		<hr/>	<hr/>
		1,000	1,000
CREDITORS: amounts falling due within one year	4	-	-
		<hr/>	<hr/>
NET CURRENT ASSETS		1,000	1,000
		<hr/>	<hr/>
TOTAL ASSETS LESS CURRENT LIABILITIES		1,000	1,000
CREDITORS: amounts falling due after more than one year	4	(58)	(58)
		<hr/>	<hr/>
		942	942
		<hr/> <hr/>	<hr/> <hr/>
FINANCED BY			
CAPITAL AND RESERVES			
Called up share capital	6	1,000	1,000
Profit and loss account		-	(58)
Reserves		(58)	-
		<hr/>	<hr/>
Shareholders' funds		942	942
		<hr/> <hr/>	<hr/> <hr/>

STATEMENT OF FINANCIAL POSITION
at 10 February 2026 (continued)

We, as Directors' of RQ Medical Limited, state that –

- (a) The company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,
- (b) The company is availing itself of the exemption on the grounds that the conditions specified in s.358 are satisfied,
- (c) The shareholders of the company have not served a notice on the company under s.334(1) in accordance with s.334(2)
- (d) We acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare Financial Statements which give a true and fair view of assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a year and to otherwise comply with the provisions of Companies Act 2014 relating to Financial Statements so far as they are applicable to the company,
- (e) The company has relied on the specified exemption contained in s.352 Companies Act 2014 (as a micro company); has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged Financial Statements have been properly prepared in accordance with s.353 Companies Act 2014.

Approved by the Board on 10 Feb 2026 and signed on its behalf by:

Directors Quintain Noonan

Quinatin Noonan
Director
10 Feb 2026

Ronan Parkin

Ronan Parkinson
Director
10 Feb 2026

STATEMENT OF CHANGES IN EQUITY
for the year ended 10 February 2026

	<i>Called-up share capital</i>	<i>Non- distributable reserve</i>	<i>Profit and loss account</i>	<i>Total equity</i>
	€	€	€	€
At 1 January 2024	1,000	-	-	1,000
Profit for the year	-	-	(58)	(58)
	-----	-----	-----	-----
At 31 December 2025	1,000	-	(58)	942
	-----	-----	-----	-----
Profit for the year	-	-	-	-
	-----	-----	-----	-----
At 10 February 2026	<u>1,000</u>	<u>-</u>	<u>(58)</u>	<u>942</u>

NOTES TO THE FINANCIAL STATEMENTS

10 February 2026

1. GENERAL INFORMATION

RQ Medical Limited is a company limited by shares incorporated in Republic of Ireland Gormlee Carriag na BhFear, Co. Cork, Ireland is the registered office, which is also the principal place of business of the company. The nature of the company's operations and its principal activities are set out in the Directors' Report. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. ACCOUNTING POLICIES

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Statement of compliance

The financial statements of the company for the year ended 10 February 2026 have been prepared on the going concern basis and in accordance with generally accepted accounting principles in Ireland and Irish statute comprising the Companies Act 2014 and in accordance with the Financial Reporting Standard applicable in the United Kingdom and the Republic of Ireland (FRS 102) issued by the Financial Reporting Council, as promulgated by Chartered Accountants Ireland

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council and promulgated by the Institute of Chartered Accountants in Ireland.

Turnover

Turnover comprises the invoice value of goods/services supplied by the company, exclusive of trade discounts and value added tax.

NOTES TO THE FINANCIAL STATEMENTS
10 February 2026 (continued)

Tangible fixed assets and depreciation

Tangible fixed assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible fixed assets, less their estimated residual value, over their expected useful lives as follows:

Fixtures, fittings and equipment	- 12.5% Straight line
Motor vehicles	- 12.5% Straight line

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

Stock

Stocks are valued at the lower of cost and net realisable value. Cost comprises expenditure incurred in the normal course of business in bringing stocks to their present location and condition. Full provision is made for obsolete and slow moving items. Net realisable value comprises actual or estimated selling price (net of trade discounts) less all further costs to completion or to be incurred in marketing and selling.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Cash and cash equivalents

Cash and cash equivalents comprise cash at bank and in hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less and bank overdrafts. In the Abridged Balance Sheet bank overdrafts are shown within Creditors.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Employee benefits

The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund.

Short term benefits, including holiday pay and other similar non-monetary benefits, are recognised as an expense in the period in which the service is rendered.

NOTES TO THE FINANCIAL STATEMENTS
10 February 2026 (continued)
Taxation and deferred taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Pensions

The company operates a defined contribution pension scheme for employees. The assets of the scheme are held separately from those of the company. Annual contributions payable to the company's pension scheme are Charged to the Profit and Loss Account in the period to which they relate.

3.	STAFF COSTS	<i>2026</i>	<i>2025</i>
		<i>Number</i>	<i>Number</i>
	<i>The average number of persons employed by the company (including directors) during the year was as follows</i>		
	Management and administration	2	2
	Operations	-	-
		<hr/>	<hr/>
		2	2
		<hr/> <hr/>	<hr/> <hr/>
	<i>The staff costs comprise:</i>	<i>2026</i>	<i>2025</i>
		€	€
	Salaries	-	-
	Social welfare costs	-	-
	Pension costs	-	-
	Other compensation costs	-	-
	– Long term incentive scheme	-	-
		<hr/>	<hr/>
		-	-
		<hr/> <hr/>	<hr/> <hr/>

NOTES TO THE FINANCIAL STATEMENTS
10 February 2026 (continued)

4.	CREDITORS	2026	2025
		€	€
	Included in creditors:		
	Amounts falling due within one year		
	Bank loans and overdrafts	-	-
	Taxation and social welfare (Note 5)	-	-
	Accruals	-	-
	Amounts falling due after one year		
	Accruals	58	58
		-----	-----
		58	58
		=====	=====
5.	TAXATION AND SOCIAL WELFARE	2026	2025
		€	€
	Creditors:		
	VAT	-	-
	PAYE	-	-
	PRSI	-	-
		-----	-----
		-	-
		=====	=====
6.	DEBTORS	2026	2025
		€	€
	Other debtors	-	-
	Prepayments and accrued income	-	-
	VAT	-	-
		-----	-----
		-	-
		=====	=====

NOTES TO THE FINANCIAL STATEMENTS
10 February 2026 (continued)

7.	SHARE CAPITAL	2026	2025
		€	€
	<i>Authorised:</i>		
	Ordinary shares of €1 each	1,000,000	1,000,000
		<u> </u>	<u> </u>
	<i>Allotted, called up and fully paid:</i>		
	Ordinary shares of €1 each	1,000	1,000
		<u> </u>	<u> </u>

The directors' interests in the shares of the company are as follows:

Name	Class of Shares	Number Held At	
		2026	2025
Quintain Noonan	Ordinary Shares of €1.00 each	675	675
Ronan Parkinson	Ordinary Shares of €1.00 each	275	275

8.	DIRECTORS'S REMUNERATION	2026	2025
		€	€
	Remuneration	-	-
	Pension contributions	-	-
		<u> </u>	<u> </u>
		-	-
		<u> </u>	<u> </u>
9.	APPROVAL OF FINANCIAL STATEMENTS		

The financial statements were approved and authorised for issue by the board of directors on 10 Feb 2026